Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
November 05, 2018 07:00 ET
|
Abeona Therapeutics Inc.
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10...
Abeona Announces Participation at Upcoming Conferences
September 28, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
September 12, 2018 08:45 ET
|
Abeona Therapeutics Inc.
Clinical trial for ABO-101 (AAV-NAGLU) marks the 2nd MPS III program in EuropeCompany plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom...
Abeona Announces Participation at Upcoming Conferences
September 04, 2018 08:45 ET
|
Abeona Therapeutics Inc.
Citi's 13th Annual Biotech Conference - September 5-6th in Boston, MAJefferies Gene Therapy Summit - September 27th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018 (GLOBE NEWSWIRE)...
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
August 09, 2018 16:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
July 26, 2018 08:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
June 06, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
May 18, 2018 09:25 ET
|
Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
May 14, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Presentations
May 08, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...